עברית

What Evidence Should Health Systems Require Before Adopting Remote Prenatal Monitoring

What each kind of evidence proves, what it leaves open, and how published studies of Pulsenmore ES illustrate each one.

TL;DR

  • Health systems should look for six kinds of evidence: regulatory authorization, clinical performance, accuracy, safety and outcomes, patient experience, and clinical implementation.
  • Each addresses a different question, so strength in one area does not cover the others.
  • Pulsenmore ES’s FDA De Novo authorization was supported by a multicenter U.S. study of 162 women and 1,370 scans, and further research covers outcomes, accuracy, anxiety, usability, and hybrid care.
  • Study design, populations, scanning modes, and workflows affect results, so independent studies with lower success rates belong in the assessment.
  • Adoption depends on safe integration into workflows, access, patient experience, and value in the health system’s own care model.

Health systems should look beyond regulatory authorization to clinical performance, safety, real-world outcomes, patient experience, and integration into routine care. Adoption also depends on clinical workflows, patient eligibility, timely interpretation, and links to in-person care.

Beyond regulatory approval: evaluating clinical readiness

Introducing a medical device into prenatal care requires more than showing that it works. Healthcare leaders must evaluate whether it performs reliably, whether patients can use it successfully, whether its use is associated with acceptable clinical outcomes, and how it fits into existing care pathways.

1. Start with regulatory authorization and intended use

In November 2025, Pulsenmore received FDA De Novo marketing authorization for its home prenatal ultrasound system. The authorization covers use in singleton pregnancies between 14 and 38 weeks of gestation, including fetal heart rate determination by healthcare professionals from home-acquired ultrasound images. The system supports two approaches: app-guided scanning, performed independently by the patient and subsequently reviewed by a clinician, and clinician-guided scanning, performed with real-time professional guidance. For healthcare organizations, the key consideration is whether the authorized indications align with the intended patient population, clinical objectives, and care delivery model.

2. Evaluate clinical performance in patients’ hands

Early research in Israel involving 100 pregnant women demonstrated the feasibility of patient-operated ultrasound, with fetal cardiac activity detected in 95.3 percent of scans. More recently, the multicenter U.S. HOLA study evaluated 162 women across four clinical institutions, generating 1,370 ultrasound scans. The study reported successful fetal cardiac activity assessment in 99.2 percent of clinician-guided scans and 96.5 percent of app-guided scans. A German feasibility study at Erlangen University Hospital reported lower detection rates in its tested setting, highlighting the importance of device selection, scanning protocols, patient training, and the availability of clinical guidance.

3. Assess accuracy and clinical reliability

Research conducted at Rabin Medical Center evaluated remote fetal heart rate measurements against conventional ultrasound examinations. Additional studies in Israel and the United States have investigated the feasibility and agreement of remotely acquired ultrasound images for assessing components of the fetal biophysical profile. These studies suggest potential applications beyond basic fetal cardiac assessment, although such applications require further evaluation and are not included in the current U.S. FDA-authorized indications for Pulsenmore ES. For decision-makers, the distinction is important: evidence supporting one clinical measurement should not automatically be extended to other diagnostic applications.

Pulsenmore’s announcement of the two biophysical profile studies summarizes the results.

4. Examine safety and pregnancy outcomes at scale

A large retrospective cohort study published in BMC Pregnancy and Childbirth compared 4,460 women using Clalit’s home ultrasound service in Israel with 102,707 non-users. The researchers found no significant differences in preterm birth or adverse neonatal outcomes between the groups.

5. Consider patient experience and psychological outcomes

A randomized clinical study published in American Journal of Obstetrics & Gynecology MFM evaluated home ultrasound among women with a history of recurrent pregnancy loss. The study reported lower maternal anxiety and improved maternal-fetal attachment in the intervention group. However, psychological outcomes should be interpreted in the context of the populations studied. Benefits observed among women with previous pregnancy loss cannot automatically be generalized to all pregnancies.

6. Look for evidence of integration into clinical practice

Successful implementation requires suitable patient selection, clinician availability, clear responsibilities for image interpretation, and established pathways for follow-up when additional evaluation is needed. In the Netherlands, prospective research has examined the feasibility and usability of clinician-guided home ultrasound, contributing evidence on patient experience and remote scanning workflows.

What each kind of evidence shows

Evidence typeKey questionExamples from Pulsenmore researchWhat remains to be evaluated
Regulatory authorizationIs the technology authorized for the intended use?FDA De Novo authorization, November 2025Applications beyond authorized indications
Clinical performanceCan patients acquire clinically useful images?HOLA multicenter U.S. study; early feasibility studiesPerformance across populations and workflows
AccuracyHow well do remote findings agree with conventional assessments?Fetal heart rate validation; exploratory BPP studiesBroader diagnostic applications
Safety and outcomesWhat happens when the technology is used in routine care?4,460 users compared with 102,707 controlsProspective comparative outcomes
Patient experienceHow does use affect patients?Studies of anxiety, maternal-fetal attachment and usabilityLong-term benefits and generalizability

At Sheba Medical Center in Israel, researchers have evaluated hybrid models combining remote monitoring with in-person maternal-fetal care. One prospective pilot involving women with gestational diabetes reported a median remote visit duration of 59 minutes, compared with 159 minutes for conventional clinic visits.

Practical Takeaways for decision-makers

Healthcare organizations should consider four priorities when assessing adoption.

Review the complete evidence base. Consider both supportive and less favorable findings.

Match the evidence to the intended care model. Results obtained with clinician-guided scanning may differ from those obtained with independent app-guided scanning.

Assess implementation requirements. Review clinician capacity, image interpretation processes, patient eligibility, connectivity, and pathways for in-person evaluation.

Define meaningful measures of success. In addition to technical performance, assess patient experience, access to care, clinical outcomes, operational efficiency, and financial sustainability.

The broader perspective

While further research is needed to establish long-term outcomes, economic value, and performance across additional populations, the available evidence provides a foundation for healthcare systems considering the integration of home ultrasound into prenatal care. The central question is no longer simply whether patients can perform ultrasound examinations at home, but how these technologies can be incorporated responsibly into clinical pathways that preserve physician-led care.

Pulsenmore’s review of three years of research and real-world application summarizes this record.

Teams evaluating home ultrasound can start at Pulsenmore’s home ultrasound page and the Pulsenmore resource center.

FAQs

Q: What does FDA De Novo authorization mean for Pulsenmore ES?

A: It means the FDA classified Pulsenmore ES as a new type of device with no legally marketed equivalent and authorized it for marketing. The authorization covers a home-use prenatal ultrasound platform with remote physician interpretation, and a physician prescription is required. The Pulsenmore handheld ultrasound system is designed in accordance with ALARA (As Low As Reasonably Achievable) principles, which guide the use of ultrasound at the lowest levels needed to obtain clinically useful images.

Q: How accurate are scans that patients take themselves?

A: Accuracy depends on the measure. A validation study compared remote fetal heart rate with standard ultrasound, and in the 100-woman study, fetal heart activity was detected in 95.3 percent of scans.

Q: What does the largest safety study show?

A: The BMC Pregnancy and Childbirth cohort found no difference in preterm birth or adverse neonatal outcomes between 4,460 users and 102,707 non-users. The study is retrospective and shows association, not causation, and the users differed from non-users in several characteristics.

Q: Has Pulsenmore ES been studied outside Israel?

A: Yes. Pulsenmore ES has been evaluated in clinical research across the U.S. and Europe. A pivotal multicenter U.S. study involving 162 women and 1,370 scans supported its FDA De Novo authorization. Additional published studies include research at Erlangen University Hospital in Germany and a prospective study in the Netherlands, while the University of Michigan investigated remote fetal biophysical profile assessments. Clinical research has also been registered in the UK, including a study at Birmingham Women’s Hospital exploring home monitoring in high-risk pregnancies. Together, these initiatives reflect growing international clinical interest in patient-operated ultrasound and its integration into prenatal care.

Q: What operational evidence exists for health systems?

A: Published research from Sheba Medical Center demonstrates how home ultrasound can be integrated into hybrid prenatal care. An initial prospective study of women with gestational diabetes reported a 97.4 percent success rate for remote visits, significantly shorter visit times (59 versus 159 minutes), and high patient satisfaction. A subsequent hospital-at-home program for high-risk pregnancies, incorporating Pulsenmore alongside other remote monitoring technologies, reported 206 admissions and nearly 3,000 days of remote care. Together, these studies provide real-world insights into the feasibility, operational efficiency, and integration of connected technologies into physician-led prenatal care.

Q: What should a health system request from Pulsenmore during evaluation?

A: Request the full publication list and each study’s protocol and limitations. The Pulsenmore resource center lists publications, and clinicians or health organizations can contact Pulsenmore through the contact form to review clinical and operational needs.